These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9689888)

  • 21. Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina.
    Arrossi S; Ramos S; Paolino M; Sankaranarayanan R
    Reprod Health Matters; 2008 Nov; 16(32):50-8. PubMed ID: 19027622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The state of the organized screening in Hungary in 2006].
    Kovács A; Döbrôssy L; Budai A; Cornides A; Boncz I
    Orv Hetil; 2007 Mar; 148(10):435-40. PubMed ID: 17350908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of self-reported cervical cancer screening and impact on cervical cancer mortality in Austria.
    Vutuc C; Haidinger G; Waldhoer T; Ahmad F; Breitenecker G
    Wien Klin Wochenschr; 1999 May; 111(9):354-9. PubMed ID: 10407996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs and benefits of cervical screening. III. Cost/benefit analysis of a call of previously unscreened women.
    Waugh N; Smith I; Robertson A; Reid GS; Halkerston R; Grant A
    Cytopathology; 1996 Aug; 7(4):249-55. PubMed ID: 8853971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cost-benefit of expanding cervical cancer screening].
    Deng J; Tan H; Yang T; Huang X; Zhou S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 May; 35(5):470-5. PubMed ID: 20543471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cost-benefit analysis of the Program for Early Screening of Cervico-uterine Cancer].
    Hernández-Peña P; Lazcano-Ponce EC; Alonso-de Ruiz P; Cruz-Valdez A; Meneses-González F; Hernández-Avila M
    Salud Publica Mex; 1997; 39(4):379-87. PubMed ID: 9381251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of cervical-cancer screening in developing countries.
    Suba EJ; Frable WJ; Raab SS
    N Engl J Med; 2006 Apr; 354(14):1535-6; author reply 1535-6. PubMed ID: 16598056
    [No Abstract]   [Full Text] [Related]  

  • 28. [A reply on cervix cancer screening: cervical cytological test doesn't fulfil the requirements of a good screening test].
    Bistoletti P
    Lakartidningen; 2000 Sep; 97(37):4042. PubMed ID: 11036367
    [No Abstract]   [Full Text] [Related]  

  • 29. Screening for cervical neoplasia. A survey of the assumptions from studies on the screening in Maribo Amt.
    Berget A
    Dan Med Bull; 1979 Nov; 26(7):313-32. PubMed ID: 118850
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost effectiveness of population screening and rescreening for cervical cancer in the Netherlands.
    Boon ME; de Graaff Guilloud JC
    Acta Cytol; 1981; 25(5):539-42. PubMed ID: 6792845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Papanicolaou cervical smears for screening in asymptomatic women.
    Barnes BA
    Prim Care; 1981 Mar; 8(1):131-40. PubMed ID: 6911755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost effectiveness of cervical cancer screening strategies in Tunisia].
    Hsaïri M; Fakhfakh R; Ghyoula M; Ben Abdallah M; Achour N
    Tunis Med; 2000 Oct; 78(10):557-61. PubMed ID: 11190738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An economic appraisal of a mobile cervical cytology screening service.
    Bloch B
    S Afr Med J; 1997 Feb; 87(2):231. PubMed ID: 9180819
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement of the cost of screening for cervical cancer in the district of Florence, Italy.
    Zappa M; Cecchini S; Ciatto S; Iossa A; Falini P; Mancini M; Paci E
    Tumori; 1998; 84(6):631-5. PubMed ID: 10080666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis.
    Accetta G; Biggeri A; Carreras G; Lippi G; Carozzi FM; Confortini M; Zappa M; Paci E
    J Med Screen; 2010; 17(4):181-9. PubMed ID: 21258128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of cervical cancer screening: comparison of screening policies.
    van den Akker-van Marle ME; van Ballegooijen M; van Oortmarssen GJ; Boer R; Habbema JD
    J Natl Cancer Inst; 2002 Feb; 94(3):193-204. PubMed ID: 11830609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience.
    Sepúlveda C; Prado R
    Cancer Detect Prev; 2005; 29(5):405-11. PubMed ID: 16188399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cervical cancer screening in Serbia.
    Kesić V; Jovićević-Bekić A; Vujnović M
    Coll Antropol; 2007 Apr; 31 Suppl 2():31-6. PubMed ID: 17598502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.